SEC EDGARAug 24$NTLA

LEONARD JOHN M sold $287K of NTLA

LEONARD JOHN M (President and CEO) sold 22,675 shares of Intellia Therapeutics, Inc. (NTLA) at an average of $12.65 ($12.60–$13.00, $0.29M total) across 2 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · LEONARD JOHN M

Published Aug 24, 2026, 8:05 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 24, 2026, 8:24 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$NTLA

Neutral

high confidence

Mentioned

$NTLA

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$NTLANeutralLow

Why it matters

The disclosed sale is modest and likely already priced in, offering limited trading edge.

Market read

Routine insider sale with minimal market impact; primarily of interest to short-term traders monitoring insider activity.

What to watch

Potential upcoming clinical data releases could outweigh the sale's relevance.

Relevance 3/10Novelty 4/10Timing: filed Aug 24 2026

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre-scheduled sales.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NTLANeutralHigh confidence

Context

CEO Leonard John M sold 22,675 shares for $286,819 via a 10b5-1 plan.

Expected impact

Minimal short-term price pressure, unlikely to move beyond normal volatility.

Evidence & confidence

Sale amount is small relative to holdings and market cap; executed under pre-arranged plan.

Market effects

Sector

No significant effect on biotech sector; typical insider sale.

Regional

Limited to US markets where NTLA trades.

Global

Negligible global impact.

Counterpoint

What could challenge this read

Some traders may view any insider selling as a bearish signal despite the 10b5-1 plan.

Key entities

Individual
Leonard John M
President and CEO of Intellia Therapeutics, Inc.
Company
Intellia Therapeutics, Inc.
Biotech firm developing CRISPR-based therapies.

Read at source ← All news

$NTLAMed

Intellia Therapeutics Announces Third Quarter 2026 Financial Results

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ

SEC EDGAR 8-KNov 5

$NTLALowAI 8/10

Intellia concludes Phase III ATTRv-PN study enrolment

Intellia Therapeutics completed patient enrolment in the Phase III MAGNITUDE-2 study for nexiguran ziclumeran (nex-z), a CRISPR-based treatment for ATTRv-PN. The trial will assess safety and efficacy in 60 adults, with primary outcomes measured at day 29 and month 18. Intellia aims to halt or reverse disease progression with a single dose. The therapy is also being studied for ATTR-CM and has received regulatory designations from the FDA and European Commission.

clinicaltrialsarena.comNov 5

$NTLAMedAI 8/10

Intellia completes enrollment in phase 3 trial for ATTRv-PN therapy

Intellia Therapeutics (NASDAQ:NTLA) completed enrollment in the MAGNITUDE-2 phase 3 trial for nex-z, a CRISPR-based therapy for ATTRv-PN. The trial involves 60 patients and evaluates efficacy and safety over 18 months. Nex-z is also being tested in a separate phase 3 trial for ATTR-CM and has received Orphan Drug and RMAT designations. Intellia collaborates with Regeneron on its development.

investing.comNov 4

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

genengnews.comNov 1

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

stocktwits.comOct 28

$NTLALow

Jing Marantz helped advance several approved rare-disease therapies. On Oct. 26, she becomes Intellia’s medical chief.

Intellia Therapeutics (NTLA) appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz brings extensive experience in rare disease therapies and will lead clinical development and regulatory affairs. The company is advancing its CRISPR gene editing pipeline, including Phase 3 trials for transthyretin amyloidosis.

stocktitan.netOct 13